Investors Overview

Corporate Profile
Cipher Pharmaceuticals is a growing specialty pharmaceutical dermatology company, with a robust and diversified portfolio of commercial and early to late-stage products. Through multiple transactions, Cipher has built its U.S. commercial presence, expanded its Canadian dermatology franchise and broadened its pipeline. Cipher is well-capitalized to drive long-term, sustained earnings growth by leveraging its proven clinical development capabilities and efficient commercial execution.

CIPHER PHARMACEUTICALS ANNOUNCES PLANS TO VOLUNTARILY DELIST FROM NASDAQ

ExchangeTSX (Canadian Dollar)
PriceCan$4.38
Change (%)0.00 (0.00%)
Volume0
Data as of 03/22/17 3:59 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle 
03/20/17Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEOPrinter Friendly Version
03/02/17Cipher Pharmaceuticals Reports 2016 Q4 & Year-End Financial ResultsPrinter Friendly Version
02/16/17Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2016 Conference CallPrinter Friendly Version
Featured Documents
Download Documentation Q4 2016 MD&A
Download Documentation Q4 Financial Statements
Download Documentation Investor Presentation - Q3 2016
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Cipher Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources